Fairmount Funds Management LLC
SEC insider (Form 3/4/5 filer). CIK 0001802528. Director & 10% Owner at Alaunos Therapeutics, Inc. (TCRT) and 9 other issuers. 49 reported Form 4/5 transactions since Sep 2024; latest on Sep 9, 2026. Located in WEST CONSHOHOCKEN, PA.
Companies Fairmount Funds Management LLC has filed insider reports for
- Alaunos Therapeutics, Inc. (TCRT): Director, 10% Owner
- Korsana Biosciences, Inc. (KRSA): Director, 10% Owner
- Apogee Therapeutics, Inc. (APGE): Director
- CRESCENT BIOPHARMA, INC. (CBIO): Director, 10% Owner
- Oruka Therapeutics, Inc. (ORKA): Director, 10% Owner
- Spyre Therapeutics, Inc. (SYRE): Director
- Jade Biosciences, Inc. (JBIO): Director, 10% Owner
- Viridian Therapeutics, Inc.\DE (VRDN): Director, 10% Owner
- Zenas BioPharma, Inc. (ZBIO): Director
- Damora Therapeutics, Inc. (DMRA): Director, 10% Owner
Fairmount Funds Management LLC
CIK: 0001802528
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (12)
Alaunos Therapeutics, Inc.
Korsana Biosciences, Inc.
Apogee Therapeutics, Inc.
CRESCENT BIOPHARMA, INC.
Oruka Therapeutics, Inc.
Spyre Therapeutics, Inc.
Jade Biosciences, Inc.
Viridian Therapeutics, Inc.\DE
Zenas BioPharma, Inc.
Damora Therapeutics, Inc.
Cogent Biosciences, Inc.
Dianthus Therapeutics, Inc. /DE/
Discretionary Trading P&L
Holdings
Transaction History (49 total)
- Sep 9, 2026KRSA
Korsana Biosciences, Inc.
AwardIndirectStock Option (Right to Buy)
48.4K shares- - Sep 3, 2026APGE
Apogee Therapeutics, Inc.
DispositionIndirect51.2K shares- - Sep 3, 2026APGE
Apogee Therapeutics, Inc.
DispositionIndirect340.9K shares- - Sep 3, 2026APGE
Apogee Therapeutics, Inc.
DispositionIndirect51.2K shares- - Aug 7, 2026APGE
Apogee Therapeutics, Inc.
ExerciseIndirect31.8K shares at avg. $17.00$541K - Aug 7, 2026APGE
Apogee Therapeutics, Inc.
ExerciseIndirect10.4K shares at avg. $43.85$455K - Jul 16, 2026CBIO
CRESCENT BIOPHARMA, INC.
PurchaseIndirect853.5K shares at avg. $14.50$12.4M - Jul 1, 2026ORKA
Oruka Therapeutics, Inc.
SaleIndirect3.6M shares at avg. $84.43$300.0M - Jul 1, 2026ORKA
Oruka Therapeutics, Inc.
ConversionIndirect3.6M shares- - Jun 23, 2026SYRE
Spyre Therapeutics, Inc.
SaleIndirect4.7M shares at avg. $85.31$399.7M
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 9, 2026 | KRSA Korsana Biosciences, Inc. | Award Stock Option (Right to Buy) | 48,445 | - | - | Indirect |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Disposition | 51,166 | - | $0 | Indirect |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Disposition | 340,855 | - | $0 | Indirect |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Disposition | 51,166 | - | $0 | Indirect |
| Aug 7, 2026 | APGE Apogee Therapeutics, Inc. | Exercise | 31,838 | $17.00 | $541,246 | Indirect |
| Aug 7, 2026 | APGE Apogee Therapeutics, Inc. | Exercise | 10,370 | $43.85 | $454,725 | Indirect |
| Jul 16, 2026 | CBIO CRESCENT BIOPHARMA, INC. | Purchase | 853,450 | $14.50 | $12,375,025 | Indirect |
| Jul 1, 2026 | ORKA Oruka Therapeutics, Inc. | Sale | 3,553,410 | $84.43 | $300,014,406 | Indirect |
| Jul 1, 2026 | ORKA Oruka Therapeutics, Inc. | Conversion | 3,553,410 | - | $0 | Indirect |
| Jun 23, 2026 | SYRE Spyre Therapeutics, Inc. | Sale | 4,684,781 | $85.31 | $399,658,667 | Indirect |
1-10 of 49 transactions